Semanteon Capital Management LP Acquires 48,184 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Semanteon Capital Management LP increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 32.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 197,760 shares of the biotechnology company’s stock after buying an additional 48,184 shares during the quarter. BioCryst Pharmaceuticals comprises about 0.8% of Semanteon Capital Management LP’s holdings, making the stock its 6th biggest position. Semanteon Capital Management LP’s holdings in BioCryst Pharmaceuticals were worth $1,487,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Teacher Retirement System of Texas lifted its holdings in shares of BioCryst Pharmaceuticals by 25.1% in the fourth quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company’s stock valued at $438,000 after buying an additional 11,711 shares during the period. Xponance Inc. raised its position in BioCryst Pharmaceuticals by 9.1% in the fourth quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 1,242 shares in the last quarter. Intech Investment Management LLC lifted its holdings in BioCryst Pharmaceuticals by 80.3% in the 4th quarter. Intech Investment Management LLC now owns 97,793 shares of the biotechnology company’s stock valued at $735,000 after acquiring an additional 43,556 shares during the last quarter. Cibc World Markets Corp bought a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $145,000. Finally, May Barnhard Investments LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $226,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

BCRX has been the topic of several research reports. Wedbush initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Needham & Company LLC increased their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Stock Up 0.8 %

NASDAQ:BCRX opened at $7.69 on Friday. The firm has a market cap of $1.61 billion, a PE ratio of -12.61 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $9.50. The company’s 50-day moving average price is $8.12 and its two-hundred day moving average price is $7.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same period last year, the company earned $0.28 earnings per share. The firm’s revenue was up 40.8% compared to the same quarter last year. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.